miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1481-1485

  Fesler, Andrew ^a   Zhai, Haiyan ^a   Ju, Jingfang ^a  

^a Stony Brook School of Dental Medicine   (United States)

Author keywords

5 FU; Biomarker; Cancer; miR 129; Therapeutics

Indexed keywords

CYCLIN DEPENDENT KINASE 6; MICRORNA; MICRORNA 129; PROTEIN BCL 2; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR SOX4; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; DRUG TARGETING; EPIGENETIC REPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; HUMAN; PREDICTIVE VALUE; REVIEW; SURVIVAL PREDICTION;

EID: 84907370457     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S65548     Document Type: Review

References (32)

1. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
2. Lee RC, Feinbaum RL, Ambros V. The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
3. Pillai RS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309(5740): 1573-1576.
4. Ruvkun G. Clarif ications on miRNA and cancer. Science. 2006; 311(5757):36-37.
5. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′UTR as in the 3′UTR. Proc Natl Acad Sci U S A. 2007;104(23):9667-9672.
6. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008;455(7216):1124-1128.
7. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A. 2008;105(5):1608-1613.
8. Kunej T, Godnic I, Horvat S, Zorc M, Calin GA. Cross talk between microRNA and coding cancer genes. Cancer J. 2012;18(3): 223-231.
9. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811.
10. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C elegans. Cell. 1993;75(5):855-862.
11. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-15529.
12. Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009;34(2): 537-542.
13. Bandres E, Agirre X, Bitarte N, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009;125(11): 2737-2743.
14. Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013;4(6):e659.
15. Tsai KW, Wu CW, Hu LY, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011;129(11): 2600-2610.
16. Liu Y, Hei Y, Shu Q, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS ONE. 2012;7(4):e35800.
17. Chen X, Hu H, Guan X, et al. CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer. 2012;130(7): 1607-1613.
18. Kang M, Li Y, Liu W, et al. miR-129-2 suppresses proliferation and migration of esophageal carcinoma cells through downregulation of SOX4 expression. Int J Mol Med. 2013;32(1):51-58.
19. Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol. 2009;42(2):102-109.
20. Yu X, Song H, Xia T, et al. Growth inhibitory effects of three miR-129 family members on gastric cancer. Gene. 2013;532(1):87-93.
21. Lu CY, Lin KY, Tien MT, Wu CT, Uen YH, Tseng TL. Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma. Genes Chromosomes Cancer. 2013;52(7): 636-643.
22. Chen X, Zhang L, Zhang T, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013;33(3):476-486.
23. Huang YW, Liu JC, Deatherage DE, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009;69(23):9038-9046.
24. Shen R, Pan S, Qi S, Lin X, Cheng S. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394(4):1047-1052.
25. Vervoort SJ, van Boxtel R, Coffer PJ. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? Oncogene. 2013;32(29):3397-3409.
26. Wu J, Qian J, Li C, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle. 2010;9(9):1809-1818.
27. Sun N, Meng Q, Tian A. Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. Am J Surg. 2010;200(3):341-345.
28. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13(10):1668-1674.
29. Cho WC. Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis. Front Genet. 2011;2:7.
30. Fesler A, Jiang J, Zhai H, Ju J. Circulating microRNA testing for the early diagnosis and follow-up of colorectal cancer patients. Mol Diagn Ther. 2014;18(3):303-308.
31. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42(8): 1273-1281.
32. Yu X, Luo L, Wu Y, et al. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol. 2013;30(1):365.